First Trust Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $82.1M | Buy |
|
|||||
|
2025
Q1 | $48.7M | Sell |
|
|||||
|
2024
Q4 | $77.1M | Buy |
|
|||||
|
2024
Q3 | $78.5M | Buy |
|
|||||
|
2024
Q2 | $58.5M | Buy |
|
|||||
|
2024
Q1 | $32.5M | Sell |
|
|||||
|
2023
Q4 | $58.7M | Buy |
|
|||||
|
2023
Q3 | $41.4M | Sell |
|
|||||
|
2023
Q2 | $52.5M | Sell |
|
|||||
|
2023
Q1 | $86.2M | Buy |
|
|||||
|
2022
Q4 | $99.9M | Sell |
|
|||||
|
2022
Q3 | $99.1M | Buy |
|
|||||
|
2022
Q2 | $58.3M | Sell |
|
|||||
|
2022
Q1 | $65.7M | Sell |
|
|||||
|
2021
Q4 | $86M | Sell |
|
|||||
|
2021
Q3 | $101M | Buy |
|
|||||
|
2021
Q2 | $85.8M | Buy |
|
|||||
|
2021
Q1 | $61M | Sell |
|
|||||
|
2020
Q4 | $73.1M | Sell |
|
|||||
|
2020
Q3 | $106M | Sell |
|
|||||
|
2020
Q2 | $120M | Sell |
|
|||||
|
2020
Q1 | $92.2M | Buy |
|
|||||
|
2019
Q4 | $68.9M | Sell |
|
|||||
|
2019
Q3 | $64.6M | Sell |
|
|||||
|
2019
Q2 | $83.7M | Sell |
|
|||||
|
2019
Q1 | $111M | Buy |
|
|||||
|
2018
Q4 | $85.9M | Buy |
|
|||||
|
2018
Q3 | $82M | Buy |
|
|||||
|
2018
Q2 | $65M | Buy |
|
|||||
|
2018
Q1 | $63.9M | Sell |
|
|||||
|
2017
Q4 | $72.6M | Sell |
|
|||||
|
2017
Q3 | $92.2M | Buy |
|
|||||
|
2017
Q2 | $50M | Sell |
|
|||||
|
2017
Q1 | $35.6M | Sell |
|
|||||
|
2016
Q4 | $27.6M | Buy |
|
|||||
|
2016
Q3 | $28.5M | Buy |
|
|||||
|
2016
Q2 | $23.2M | Sell |
|
|||||
|
2016
Q1 | $28.9M | Sell |
|
|||||
|
2015
Q4 | $115M | Sell |
|
|||||
|
2015
Q3 | $126M | Buy |
|
|||||
|
2015
Q2 | $186M | Buy |
|
|||||
|
2015
Q1 | $131M | Buy |
|
|||||
|
2014
Q4 | $83.2M | Buy |
|